Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.61 |
| ▸ | NPC1 | O15118 | 4/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5381046 | 0.88 | KDM4E (0.69) | RAB9ANPC1KDM4EKMT2APOLB | |
| SCHEMBL14559576 | 0.80 | MAPK1 (0.62) | RAB9ANPC1KDM4EKMT2APOLB | |
| SCHEMBL4237518 | 0.80 | RAB9A (0.56) | RAB9ANPC1KDM4EKMT2APOLB | |
| SCHEMBL29128663 | 0.78 | KDM4E (0.54) | RAB9ANPC1KDM4EKMT2APOLB | |
| SCHEMBL30593991 | 0.78 | RAB9A (0.57) | RAB9ANPC1KDM4EKMT2APOLB | |
| SCHEMBL1934753 | 0.78 | RAB9A (0.57) | RAB9ANPC1KDM4EKMT2APOLB | |
| SCHEMBL3804620 | 0.77 | RAB9A (0.74) | RAB9ANPC1KDM4EKMT2APOLB | |
| SCHEMBL11115961 | 0.76 | RAB9A (1.00) | RAB9ANPC1KDM4EKMT2APOLB | |
| SCHEMBL25097159 | 0.76 | KMT2A (0.54) | RAB9ANPC1KDM4EKMT2APOLB | |
| SCHEMBL5139472 | 0.76 | KMT2A (0.54) | RAB9ANPC1KDM4EKMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112472699-A | Combination methods for improving the therapeutic benefit of bisantrene and derivatives | 种族肿瘤学公司 | 2021-03-12 | — | — | CN | disclosed |
| WO-2021018195-A1 | NOVEL TRICYCLIC COMPOUNDS AS BCR-ABL INHIBITORS | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2021-02-04 | — | — | WO | disclosed |